본문 바로가기
KERD
논문KCI 등재

Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay

이호영|김휘영|김지원|정용진|김원|서지연|김병관|조유리|이국래|진은효|정지봉|정광현
거트앤리버 소화기연관학회협의회|2015.09|Gut and Liver|제9권 제5호|pp. 657-664

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

DNAHepatitis B virusHepatitis B surface antigensImmunoradiometric assay

초록

Background/Aims: Quantification of hepatitis B surface antigen (HBsAg) is an emerging serologic test and may be useful for identifying treatment strategies for chronic hepatitis B (CHB). This study aimed to evaluate HBsAg titers during the natural course of CHB and identify correlations between HBsAg titers and hepatitis B virus (HBV) DNA concentrations across different CHB phases measured using an immunoradiometric assay (IRMA). Methods: CHB phases were defined on the basis of HBV DNA concentrations, the presence of hepatitis B e antigen/antibody (HBeAg/Ab) and serum alanine aminotransferase levels. Serum HBsAg titers and paired HBV DNA concentrations in the different phases of CHB were compared using 627 serum samples. Results: Mean HBsAg titers were significantly higher in the immunotolerant (IT) phase and immunoreactive (IR) HBeAg-positive phase than in the low-replicative (LR) and HBeAg-negative CHB (ENH) states. The correlation between HBsAg titers and HBV DNA concentrations was modest in the IT (n=36, r=0.804, p<0.001) and IR (n=48, r=0.773, p<0.001) phases, and it was poor in the LR state (n=116, r=0.289, p=0.002); however, no significant correlation was observed in the ENH state (n=67, r=0.146, p=0.237) or in the oral nucleos(t)ide analogue-treated group (n=267). Conclusions: HBsAg quantification using IRMA might be useful for discriminating different CHB phases and different stages of chronic liver disease.

Abstract

Background/Aims: Quantification of hepatitis B surface antigen (HBsAg) is an emerging serologic test and may be useful for identifying treatment strategies for chronic hepatitis B (CHB). This study aimed to evaluate HBsAg titers during the natural course of CHB and identify correlations between HBsAg titers and hepatitis B virus (HBV) DNA concentrations across different CHB phases measured using an immunoradiometric assay (IRMA). Methods: CHB phases were defined on the basis of HBV DNA concentrations, the presence of hepatitis B e antigen/antibody (HBeAg/Ab) and serum alanine aminotransferase levels. Serum HBsAg titers and paired HBV DNA concentrations in the different phases of CHB were compared using 627 serum samples. Results: Mean HBsAg titers were significantly higher in the immunotolerant (IT) phase and immunoreactive (IR) HBeAg-positive phase than in the low-replicative (LR) and HBeAg-negative CHB (ENH) states. The correlation between HBsAg titers and HBV DNA concentrations was modest in the IT (n=36, r=0.804, p<0.001) and IR (n=48, r=0.773, p<0.001) phases, and it was poor in the LR state (n=116, r=0.289, p=0.002); however, no significant correlation was observed in the ENH state (n=67, r=0.146, p=0.237) or in the oral nucleos(t)ide analogue-treated group (n=267). Conclusions: HBsAg quantification using IRMA might be useful for discriminating different CHB phases and different stages of chronic liver disease.

참고문헌 (45)

  1. Lavanchy D, "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures", J Viral Hepat, 11, pp.97~107 (2004)
  2. Lok AS, "Chronic hepatitis B", Hepatology, 45, pp.507~539 (2007)
  3. Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
  4. 이초이, "Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s", t)ide Treatment Failure, 2014, pp.8(1), 64~69[DOI]
  5. 권대훈, "Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response", Gut and Liver, 7(6), pp.712~718 (2013), 거트앤리버 발행위원회
  6. Idilman R, "Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients", J Viral Hepat, 19, pp.220~226 (2012)
  7. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
  8. Wursthorn K, "Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B", Hepatology, 44, pp.675~684 (2006)
  9. Volz T, "Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients", Gastroenterology, 133, pp.843~852 (2007)
  10. Chan HL, "Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients", Antivir Ther, 16, pp.1249~1257 (2011)
  11. Liang Y, "Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy", Aliment Pharmacol Ther, 34, pp.344~352 (2011)
  12. Ganji A, "Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV", Hepat Mon, 11, pp.342~345 (2011)
  13. Lee JH, "Correlation between quantitative serum HBsAg and HBV DNA test in Korean patients who showed high level of HBsAg", J Clin Pathol, 63, pp.1027~1031 (2010)
  14. Moucari R, "Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B", Liver Int, 31(1), pp.122~128 (2011)
  15. Nguyen T, "Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia", J Hepatol, 52, pp.508~513 (2010)
  16. Chan HL, "A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B", Hepatology, 52, pp.1232~1241 (2010)
  17. Jaroszewicz J, "Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective", J Hepatol, 52, pp.514~522 (2010)
  18. Thompson AJ, "Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers", Hepatology, 51, pp.1933~1944 (2010)
  19. 강건욱, "Quantitative Measurement of Serum Hepatitis B Surface Antigen Using an Immunoradiometric Assay in Chronic Hepatitis B", Nuclear Medicine and Molecular Imaging, 45(1), pp.15~20 (2011), 대한핵의학회
  20. Kim H, "Comparison of the Abbott Architect i2000 assay, the Roche Modular Analytics E170 assay, and an immunoradiometric assay for serum hepatitis B virus markers", Ann Clin Lab Sci, 37, pp.256~259 (2007)
  21. Wursthorn K, "Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum", J Clin Virol, 50, pp.292~296 (2011)
  22. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
  23. 조지현, "B형간염바이러스 유전자형의 국내 분포에 대한 연구", Clinical and Molecular Hepatology, 15(2), pp.140~147 (2009), 대한간학회
  24. Song BC, "Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection", Intervirology, 48, pp.133~137 (2005)
  25. Lee JM, "Quantification of HBsAg: basic virology for clinical practice", World J Gastroenterol, 17, pp.283~289 (2011)
  26. Ganem D, "Hepatitis B virus infection: natural history and clinical consequences", N Engl J Med, 350, pp.1118~1129 (2004)
  27. Ribeiro RM, "Dynamics of hepatitis B virus infection", Microbes Infect, 4, pp.829~835 (2002)
  28. Dienes HP, "Hepatic expression patterns of the large and middle hepatitis B virus surface proteins in viremic and nonviremic chronic hepatitis B", Gastroenterology, 98, pp.1017~1023 (1990)
  29. Lau JY, "Export of intracellular HBsAg in chronic hepatitis B virus infection is related to viral replication", Hepatology, 14, pp.416~421 (1991)
  30. Thimme R, "CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection", J Virol, 77, pp.68~76 (2003)
  31. Liaw YF, "Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy", J Gastroenterol Hepatol, 18, pp.246~252 (2003)
  32. Chu CM, "Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion", J Clin Microbiol, 40, pp.16~21 (2002)
  33. Yuen MF, "Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus", J Infect Dis, 186, pp.1335~1338 (2002)
  34. Liaw YF, "Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study", Hepatology, 13, pp.627~631 (1991)
  35. Chan HL, "Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response", Clin Gastroenterol Hepatol, 5, pp.1462~1468 (2007)
  36. Fattovich G, "Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years", Gut, 57, pp.84~90 (2008)
  37. Hsu YS, "Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B", Hepatology, 35, pp.1522~1527 (2002)
  38. Chu CM, "HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up", Hepatology, 45, pp.1187~1192 (2007)
  39. Manno M, "Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years", Gastroenterology, 127, pp.756~763 (2004)
  40. Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149 (2012)
  41. Tseng TC, "Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads", Hepatology, 57, pp.441~450 (2013)
  42. Brunetto MR, "Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B", Hepatology, 49, pp.1141~1150 (2009)
  43. Moucari R, "Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients", Hepatology, 49, pp.1151~1157 (2009)
  44. 권정현, "The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting", Gut and Liver, 7(2), pp.197~205 (2013), 거트앤리버 발행위원회
  45. Seto WK, "Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy", Hepatology, 58, pp.923~931 (2013)

이 간행물의 다른 논문 (17건)

Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?한동수, 은창수pp. 567-568Endoscopic Retrograde Cholangiopancreatography during Pregnancy: Really Guarantee to Safety?박은택pp. 569-570Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future DirectionsJames J. Farrellpp. 571-589Review of Pure Endoscopic Full-Thickness Resection of the Upper Gastrointestinal TractTsutomu Masaki, Hideki Kobara, Shintaro Fujihara, Noriko Nishiyama, Hirohito Moripp. 590-600Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study천재희, 홍성필, 박수정, 김태일, 김원호, 김덕환, 김은혜pp. 601-606
원문 보기